secwatch.observer — SEC 8-K summary
======================================

Issuer:     Entrada Therapeutics, Inc. (TRDA)
CIK:        0001689375
Form:       8-K
Filed at:   2022-12-19T23:59:59+00:00
Accession:  0001104659-22-128270
Event type: regulatory
Sentiment:  negative
Materiality: 0.80
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Entrada receives FDA clinical hold on IND for ENTR-601-44 in Duchenne muscular dystrophy
--------------------------------------------------------------------------------

- Clinical hold placed on IND for ENTR-601-44, a potential treatment for DMD with exon 44 skippable mutations.
- FDA to provide official clinical hold letter within 30 days; Entrada will work to address concerns.
- No approved therapies exist for patients with exon 44 skippable mutations.
- Entrada plans to share updates after further communications with the FDA.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1689375/000110465922128270/0001104659-22-128270-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1689375/000110465922128270/tm2233021d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-22-128270

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer